John Overdeck’s ACELYRIN SLRN Stock Holding History

John Overdeck’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-123,470	Closed	-$545K	–	3321
2024 Q2	$545K	Buy	+123,470	New	+$579K	﹤0.01%	2324

Other funds holding SLRN

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $426M AUM 838% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

John Overdeck's SLRN Position: Q3 2024 in Review

John Overdeck sold out of ACELYRIN (SLRN) in Q3 2024, closing a stake of 123,470 shares — an estimated $545K sold.

John Overdeck first reported a position in SLRN in Q2 2024 and held it in 1 quarter. The position peaked at $545K in Q2 2024. 122 funds tracked by Wall St. Rank hold SLRN as of Q3 2024.

John Overdeck reported no remaining ACELYRIN position as of Q3 2024 after selling out during the quarter.
John Overdeck sold 123,470 ACELYRIN shares in Q3 2024, an estimated $545K.
John Overdeck first reported a position in ACELYRIN in Q2 2024 and held it in 1 quarter.
John Overdeck's ACELYRIN position peaked at $545K in Q2 2024.
122 funds tracked by Wall St. Rank held ACELYRIN as of Q3 2024.

Based on Two Sigma Investments's 13F filing for Q3 2024, filed 14 Nov 2024.